コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 can promote platelet activation through the P2X1 receptor.
2 cessibility of cysteine mutants at the human P2X1 receptor.
3 TAC, in addition to the previously described P2X1 receptor.
4 nerves, causes vasoconstriction largely via P2X1 receptors.
5 was reduced 50% by GsMTx-4, independently of P2X1 receptors.
6 SP90 inhibitors consistent with an effect on P2X1 receptors.
7 effect on both recombinant and native human P2X1 receptors.
8 striction through ATP-mediated activation of P2X1 receptors.
9 ist, through its effects on P2Y1, P2Y12, and P2X1 receptors.
10 onding 5-methylphosphonate was equipotent at P2X1 receptors.
11 noreactivity for both P2X2 and P2X3, but not P2X1, receptors.
13 These receptors co-exist with ligand-gated P2X1 receptors activated by ATP analogs and high levels
14 Ca(2+) response was predominantly because of P2X1 receptors activated by ATP release via a phospholip
16 s study reveals a novel inhibitory effect of P2X1 receptor activation on subsequent increases in musc
18 and alpha, beta-methylene-ATP (40 microM), a P2X1 receptor agonist, had no effect on ADP-induced plat
24 cal studies have indicated expression of the P2X1 receptor, an ATP-gated cation channel, in human and
25 X receptor that has the properties of cloned P2X1 receptors and is similar to native receptors in smo
27 splayed an IC50 value of 9 nM at recombinant P2X1 receptors and was 1300-, 16-, and > 10,000-fold sel
29 selective antagonists in regulating platelet P2X1 receptors, and their potential effects on hemostasi
30 hat inhibition of HIV-1 fusion by a specific P2X1 receptor antagonist, NF279, is due to the blocking
33 nd suggest that the development of selective P2X1 receptor antagonists may provide an effective non-h
35 tent inhibition of HIV-1 fusion by selective P2X1 receptor antagonists, including NF279, and suggeste
36 ithin the second transmembrane domain of the P2X1 receptor appeared to confer on the receptor the ina
39 /mobilization demonstrated that the platelet P2X1 receptors are pharmacologically distinct from the w
41 membranes with endoglycosidase-F causes the P2X1 receptor band to migrate as a 46-kD protein, verify
42 danamycin almost abolished this movement for P2X1 receptors but had no effect on P2X2 receptor traffi
44 This study demonstrates that in neurons, the P2X1 receptor can contribute to the properties of hetero
45 he carboxyl terminus that slowed recovery of P2X1 receptor currents (7-fold less recovery at 30 secon
48 a,beta-meATP) sensitive, and in neurons from P2X1 receptor-deficient mice the alpha,beta-meATP respon
51 tions in the extracellular loop of the human P2X1 receptor during not only agonist binding and desens
52 and blood platelets, the relative levels of P2X1 receptor expression and function in human blood leu
54 platelets, we show that maximally activated P2X1 receptors failed to stimulate significant aggregati
55 latively selective pharmacological probes of P2X1 receptors, filling a long-standing need in the P2 r
57 trical field stimulation, suggesting altered P2X1 receptor function with a propensity to desensitize.
58 that NTPDase1 is required to maintain normal P2X1 receptor functionality in the vas deferens and that
59 receptors, suggesting the downregulation of P2X1 receptor gene expression during the differentiation
63 nd characterized genomic clones of the human P2X1 receptor (hP2X1) gene in an effort to understand it
64 The potency of compound 3 at the recombinant P2X1 receptor (IC50 10.2 +/- 2.6 microM) was lower than
67 rted by the lack of detectable expression of P2X1 receptors in cells used in fusion experiments and b
68 port that there is significant expression of P2X1 receptors in human platelets, but not in neutrophil
71 colocalized with somatostatin and purinergic P2X1 receptor-IR but not with tyrosine hydroxylase-IR.
72 periments conducted in this study imply that P2X1 receptor is not expressed in target cells or involv
73 icates that Schiff's base formation with the P2X1 receptor is not necessarily required for recognitio
74 agents that potentiate the actions of ATP at P2X1 receptors may be useful in the treatment of male in
77 immunoblot analysis and functional assays of P2X1 receptor-mediated ionic fluxes, we report that ther
79 unoblot analysis indicated that the platelet P2X1 receptor migrates as an approximately 60-kD protein
81 mice, we demonstrate that the absence of the P2X1 receptor on neutrophils was responsible for this de
83 ps from wild type mice and mice deficient in P2X1 receptors (P2X1(-/-)) before and after pharmacologi
86 production, ATP release, and stimulation of P2X1 receptors represent a standby purinergic signaling
89 2X receptors with a phenotype resembling the P2X1 receptor subtype on cerebral resistance arterioles.
91 express functionally significant numbers of P2X1 receptors, suggesting the downregulation of P2X1 re
92 tant Ca(2+) mobilization pathways, including P2X1 receptors, that may be particularly important durin
93 out affecting the percentage contribution of P2X1 receptors to collagen-evoked Ca(2+) responses, indi
94 n leads to rapid engagement of smooth muscle P2X1 receptors to increase action potentials (Ca(2+) fla
95 expression for the ligand-gated ion channel P2X1 receptor was detected in rat, but not mouse, thymoc
96 e cation channels from the rat vas deferens (P2X1 receptors) were stably expressed in HEK 293 cells,
97 tracellular ligand-binding loop of the human P2X1 receptor, which is inhibited by NF449, suramin, and
98 Healthy human eosinophils express functional P2X1 receptors whose activation leads to eosinophil alph
99 e potentiator of ATP-evoked responses at rat P2X1 receptors with an EC50 value of 5.9 +/- 1.8 microM,
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。